NUVL · As filed with the SEC
Nuvalent cash flow statement, by fiscal year
The statement as Nuvalent presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | (425,377,000) | (260,756,000) | (126,219,000) | (81,854,000) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Change in fair value of preferred stock tranche rights | — | — | — | 0 |
| Stock-based compensation expense | 86,502,000 | 60,579,000 | 25,563,000 | 10,325,000 |
| Net accretion on marketable securities | — | (14,669,000) | (10,109,000) | (373,000) |
| Net accretion on marketable securities | (11,107,000) | — | — | — |
| Change in fair value of related party revenue share liability | 55,220,000 | 17,940,000 | — | — |
| Other non-cash | 345,000 | — | — | — |
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current assets | (6,342,000) | (7,563,000) | 644,000 | (1,491,000) |
| Other assets | (10,508,000) | (3,408,000) | (1,428,000) | (1,272,000) |
| Accounts payable | 24,599,000 | (4,049,000) | 2,169,000 | 4,212,000 |
| Accrued expenses | — | 26,862,000 | 9,641,000 | 5,482,000 |
| Accrued expenses and other liabilities | 11,459,000 | — | — | — |
| Net cash used in operating activities | (275,209,000) | (185,064,000) | (99,739,000) | (64,971,000) |
| Cash flows from investing activities: | ||||
| Purchases of marketable securities | (1,057,766,000) | (1,024,963,000) | (459,486,000) | (212,916,000) |
| Proceeds from maturities and sales of marketable securities | 933,689,000 | 451,449,000 | 315,959,000 | 202,251,000 |
| Net cash used in investing activities | (124,077,000) | (573,514,000) | (143,527,000) | (10,665,000) |
| Cash flows from financing activities: | ||||
| Proceeds from issuance of common stock, net | 515,722,000 | 569,987,000 | 324,300,000 | 248,630,000 |
| Proceeds from exercise of stock options | — | — | 13,793,000 | 1,840,000 |
| Proceeds from issuance of common stock under employee stock purchase plan | — | — | 387,000 | — |
| Payments of equity issuance costs | (382,000) | (483,000) | (856,000) | (644,000) |
| Payments of insurance costs financed by a third-party | 0 | (622,000) | (777,000) | (910,000) |
| Net cash provided by financing activities | 515,340,000 | 568,882,000 | 336,847,000 | 248,916,000 |
| Net increase (decrease) in cash and cash equivalents | 116,054,000 | (189,696,000) | 93,581,000 | 173,280,000 |
| Cash and cash equivalents at beginning of period | 145,691,000 | 335,387,000 | 241,806,000 | 68,526,000 |
| Cash and cash equivalents at end of period | 261,745,000 | 145,691,000 | 335,387,000 | 241,806,000 |
| Supplemental disclosure of noncash investing and financing information: | ||||
| Operating lease right-of-use asset | 798,000 | — | — | — |
| Equity issuance costs | 336,000 | 6,000 | — | — |
| Insurance premium financed by a third-party | 0 | 0 | 1,399,000 | 1,820,000 |
| Public offering costs included in accounts payable | — | — | — | 90,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.